Page 3 - Yihai Cao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yihai cao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yihai Cao Today - Breaking & Trending Today

Anticancer drug may improve outcome for severe Covid patients

LONDON
Treating severe Covid-19 patients with an anticancer drug may reduce mortality and speed up recovery, a new study suggests.
According to a small clinical study, published in the journal Natur ....

City Of , United Kingdom , Karolinska Institutet , Yihai Cao , Nature Communications , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , இயற்கை தகவல்தொடர்புகள் ,

Anticancer drug may improve outcome for severe COVID-19 patients


Date Time
Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications.
Yihai Cao, photo: Ulf Sirborn
“To reduce COVID-19 mortality, we aim to develop an effective therapeutic paradigm for treating patients with severe COVID-19,” says corresponding author Yihai Cao, professor of vascular biology at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet. “Our findings suggest that bevacizumab plus standard care is highly beneficial for patien ....

Xu Jing , Yuan Zhang , Feng Xu , Xiang Ji , Ying Zhang , Jun Chen , Ming Lu , Giovanni Damiani , Jie Wei , Shuo Wu , Miriam Revera , Margherita Canesi , Yuguo Chen , Zhao Wang , Bailu Wang , Dexin Yu , Alberto Fumagalli , Karolinska Institutet , Attila Kovacs , Yihai Cao , Ulf Sirborn , Giuseppe Valmadre , Gianmarco Aondio , Ryu Li , Nature Communications , Swedish Cancer Foundation ,